STOCK TITAN

DNA X approves stock-linked cash award for acting CEO

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

DNA X, Inc. (SONM) approved a substitute cash award for Mike Mulica, its acting Chief Executive Officer and Executive Chairman, in place of an annual restricted stock unit grant because shares were unavailable under the company’s 2019 Equity Incentive Plan. The award methodology uses cash-settled Phantom RSUs valued at $50,000 based on the common stock’s fair market value on November 14, 2026.

The Phantom RSUs vest in full at the earlier of the company’s 2027 annual meeting of stockholders or a change in control. The cash award will equal the stock’s fair market value at that vesting event multiplied by the number of Phantom RSUs, payable as of the event and subject to Mr. Mulica’s continued service through it.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Phantom RSU valuation $50,000 Cash-settled Phantom RSUs valued using the common stock’s fair market value on November 14, 2026.
restricted stock units (RSUs) financial
"annual grant of restricted stock units (“RSUs”)"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Phantom RSUs financial
"cash-settled RSUs valued at $50,000 ... (the “Phantom RSUs”)"
change in control financial
"a change in control of the Company"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
fair market value financial
"fair market value of the Company’s common stock"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much was Mike Mulica’s SONM substitute cash grant?

The award methodology starts with cash-settled Phantom RSUs valued at $50,000 using the common stock’s fair market value on November 14, 2026. The eventual cash payment is calculated using the stock’s fair market value at the vesting event and the number of Phantom RSUs.

When do Mike Mulica’s SONM Phantom RSUs vest?

They vest in full at the earlier of the company’s 2027 annual meeting of stockholders or a change in control. Payment is subject to Mr. Mulica’s continued service through that event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001178697 0001178697 2026-11-14 2026-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2026

 

 

 

DNA X, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38907   94-3336783
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
         

4445 Eastgate Mall

Suite 200, San Diego, California

      92121
(Address of Principal Executive Offices)       (Zip Code)

 

 

Registrant’s Telephone Number, Including Area Code: (661) 618-7580

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common Stock, $0.001 par value   SONM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 14, 2026, the compensation committee (the “Committee”) of the board of directors (the “Board”) of DNA X, Inc. (the “Company”) approved the grant of a cash award (the “Substitute Cash Grant”) to Mike Mulica, the Company’s acting Chief Executive Officer and Executive Chairman, in lieu of an annual grant of restricted stock units (“RSUs”) under the Company’s 2019 Equity Incentive Plan (the “EIP”) due to the unavailability of shares of common stock under the EIP. The amount of the Substitute Cash Grant will be determined using the following methodology, which was designed to closely replicate RSU vesting under the Company’s current non-employee director compensation policy:

 

Assumptions:

 

(i)A number of cash-settled RSUs valued at $50,000, based on the fair market value of the Company’s common stock on November 14, 2026, the date of Committee approval (the “Phantom RSUs”), has been granted.
   
(ii)The Phantom RSUs will vest in full upon the earlier of (x) the Company’s 2027 annual meeting of stockholders and (y) a change in control of the Company (the “Vesting Event”).

 

Calculation:

 

The Substitute Cash Grant will equal the fair market value of the Company’s common stock at the time of the Vesting Event multiplied by the number of Phantom RSUs and will be payable as of the Vesting Event, subject to Mr. Mulica’s continued service through such Vesting Event.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DNA X, INC.
     
Date: November 16, 2026 By: /s/ Clayton Crolius
  Name: Clayton Crolius
  Title: Chief Financial Officer

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading